Cartesian shares updated Phase IIb Descartes-08 data and announces Phase III trial plans
Cartesian Therapeutics observed that patients still experienced clinically meaningful responses to Descartes-08 at month 12.
Cell & Gene Therapy
FDA shares additional draft guidance on CGTs
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
Resolution scores $83m to develop macrophage cell therapies
Genespire raises $52m in Series B to trial paediatric gene therapy
Q2 2024 update: cell & gene therapy related hiring actvity in the pharma industry
APAC leaps ahead in adoptive cell therapy space
